Möchten Sie immer auf dem neuesten Stand bleiben?

Enables women to access a solution that they want and needCreates an opportunity to accelerate revenue generation from this proprietary formulation Daré expects to start recording revenue and cash...

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at...

Ongoing Phase 1 study is funded by a foundation grant Daré received a royalty-free, exclusive license to the US patents SAN DIEGO and LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) --...

DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management Essentially all...

The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health series at this year’s conference to highlight the importance of...

FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA...

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that additional data from the...

Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering...

Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3...

- Grant funds will support activities that will aid in the identification and development of a novel non-hormonal intravaginal contraceptive product candidate. - Grant will also provide funding to...